Paper Details

  1. Home
  2. Paper Details

Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.

Author: AbramsonN, BennettJ M, HortonJ, LurieP, MietlowskiW L, SchillingA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study of patients with previously untreated multiple myeloma found that BCP and AP were comparable in terms of induction response rates, remission duration, and survival. However, BCP was associated with less hematologic toxicity.
Paper Details　
Original Abstract of the Article :
A prospective randomized trial in patients with previously untreated multiple myeloma was performed comparing carmustine (BCNU), cyclophosphamide, and prednisone (BCP) to melphalan (Alkeran) and prednisone (AP). Induction response rates, remission duration, and survival were similar with both regime...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7044535

データ提供：米国国立医学図書館（NLM）

Fighting Myeloma: A Head-to-Head Showdown

Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow. This study compared two treatment regimens for previously untreated multiple myeloma: carmustine (BCNU), cyclophosphamide, and prednisone (BCP) versus melphalan (Alkeran) and prednisone (AP). The study found that both regimens had similar induction response rates, remission duration, and survival. However, AP was associated with greater hematologic toxicity than BCP. The study concluded that BCP can be used as initial therapy for myeloma due to its comparable efficacy and lower hematologic toxicity.

BCP Emerges as a Promising Option

This study provides valuable insights into the treatment of multiple myeloma. The researchers found that BCP, with its comparable efficacy and lower hematologic toxicity, offers a promising treatment option for patients with previously untreated multiple myeloma. This research contributes to the ongoing quest for better treatments for multiple myeloma.

A Light in the Desert of Cancer Treatment

This study provides a beacon of hope for patients with multiple myeloma. The findings suggest that BCP could be an effective and less toxic treatment option. It's like finding a hidden oasis in the vast desert of cancer treatment.

Dr. Camel's Conclusion

This study finds that BCP is an effective treatment option for multiple myeloma. It's like finding a new trail that leads to a hidden oasis of hope for patients with this disease. This research contributes to the ongoing search for better treatments for multiple myeloma.

Date :
  1. Date Completed 1982-08-07
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

7044535

DOI: Digital Object Identifier

7044535

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.